Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2023-03-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
关于使用部分闲置自有资金进行理财管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the decision to use part of its idle funds for financial management, including investment in low-risk financial products. It details the board and supervisory committee approvals, risk control measures, and impact on daily operations. There are no financial statements or detailed financial data presented. The document is a formal announcement of a financing-related decision rather than a report or detailed financial disclosure. It fits best under Capital/Financing Update (CAP) as it relates to the company's capital management activities and investment of idle funds.
2023-03-27 Chinese
年度募集资金使用鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed report titled "关于启迪药业集团股份公司 2022 年度募集资金存放与使用情况 专项报告的鉴证报告" which translates to "Verification Report on the 2022 Annual Fundraising Funds Deposit and Usage Special Report of Qidi Pharmaceutical Group Co., Ltd.". It includes detailed information about the company's fundraising activities, the management and use of raised funds, compliance with regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and an auditor's verification opinion. The document contains extensive financial data and analysis related to the use of fundraising proceeds for the fiscal year 2022. It is not a simple announcement or certification but a full verification report on the use of capital raised by the company. This fits the category of an Audit Report / Information (AR), as it is a standalone audit/verification report on the use of raised funds, not a full annual report or interim report. The document length (11588 characters) and content confirm it is a full report, not just an announcement or certification letter. Therefore, the correct classification is AR with high confidence. FY 2022
2023-03-27 Chinese
关于广东先通药业有限公司业绩承诺完成情况审核报告
Regulatory Filings
2023-03-27 Chinese
关于公司向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about its intention to apply for a comprehensive credit facility from banks, including details about the credit limit and authorization for representatives to handle the application. It does not contain financial statements or results, nor is it a report or presentation. It is an update on financing activities related to credit facilities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and focused on financing, not a report publication or regulatory filing. Confidence is high due to clear content matching CAP definition.
2023-03-27 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is an independent director's annual performance report for the year 2022. It details the independent directors' attendance at board meetings, their opinions on various board resolutions, their training, and their role in protecting investor rights. It references the company's annual report preparation process but does not contain the annual report itself or detailed financial statements. The document is a governance-related report focusing on board activities and oversight rather than financial results or audit findings. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports.
2023-03-27 Chinese
独立董事关于第九届董事会第七次会议相关事项的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions related to the appointment of the company's 2023 audit firm. It discusses the qualifications of the audit firm and the agreement to submit the appointment proposal to the board meeting. The document is short (284 characters) and does not contain any financial data or audit results itself. It is not the audit report but rather an approval opinion related to audit matters. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory announcement related to audit firm appointment, not the audit report itself.
2023-03-27 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.